Differential Antigen Processing by Dendritic Cell Subsets in Vivo by 諛뺤콈洹�
DOI: 10.1126/science.1136080
, 107 (2007);315 Science
 et al.Diana Dudziak
Differential Antigen Processing by Dendritic Cell Subsets in Vivo
 This copy is for your personal, non-commercial use only.
 clicking here.colleagues, clients, or customers by 
, you can order high-quality copies for yourIf you wish to distribute this article to others
 
 here.following the guidelines 
 can be obtained byPermission to republish or repurpose articles or portions of articles
 
 ): June 10, 2014 www.sciencemag.org (this information is current as of
The following resources related to this article are available online at
 http://www.sciencemag.org/content/315/5808/107.full.html
version of this article at: 
including high-resolution figures, can be found in the onlineUpdated information and services, 
http://www.sciencemag.org/content/suppl/2007/01/02/315.5808.107.DC1.html 
can be found at: Supporting Online Material 
 http://www.sciencemag.org/content/315/5808/107.full.html#related
found at:
can berelated to this article A list of selected additional articles on the Science Web sites 
 http://www.sciencemag.org/content/315/5808/107.full.html#ref-list-1
, 14 of which can be accessed free:cites 27 articlesThis article 
241 article(s) on the ISI Web of Sciencecited by This article has been 
 http://www.sciencemag.org/content/315/5808/107.full.html#related-urls
100 articles hosted by HighWire Press; see:cited by This article has been 
 http://www.sciencemag.org/cgi/collection/immunology
Immunology
subject collections:This article appears in the following 
registered trademark of AAAS. 
 is aScience2007 by the American Association for the Advancement of Science; all rights reserved. The title 
CopyrightAmerican Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. 
(print ISSN 0036-8075; online ISSN 1095-9203) is published weekly, except the last week in December, by theScience 
 
o
n
 J
un
e 
10
, 2
01
4
w
w
w
.s
ci
en
ce
m
ag
.o
rg
D
ow
nl
oa
de
d 
fro
m
 
 
o
n
 J
un
e 
10
, 2
01
4
w
w
w
.s
ci
en
ce
m
ag
.o
rg
D
ow
nl
oa
de
d 
fro
m
 
 
o
n
 J
un
e 
10
, 2
01
4
w
w
w
.s
ci
en
ce
m
ag
.o
rg
D
ow
nl
oa
de
d 
fro
m
 
 
o
n
 J
un
e 
10
, 2
01
4
w
w
w
.s
ci
en
ce
m
ag
.o
rg
D
ow
nl
oa
de
d 
fro
m
 
 
o
n
 J
un
e 
10
, 2
01
4
w
w
w
.s
ci
en
ce
m
ag
.o
rg
D
ow
nl
oa
de
d 
fro
m
 
 
o
n
 J
un
e 
10
, 2
01
4
w
w
w
.s
ci
en
ce
m
ag
.o
rg
D
ow
nl
oa
de
d 
fro
m
 
tion. The nfr1, nfr5, symrk, and ccamkmutants are
unable to form nodules in response to rhizobia
inoculation. Thus, nodule formation on the snf2
transgenic roots could not have resulted from
contaminating rhizobia. In nin and nsp2 mutants
arrested before initiation of cell division induced
by Nod-factor signaling, no spontaneous nodules
were observed in snf2 transgenic roots. Because
A. rhizogenes–induced roots only develop when
the hypocotyl wound site infection is used in lotus
and because the snf2 gene constructwas integrated
into the T-DNA, these results show that cytokinin
signal perception acts upstream of cell division
initiation (table S2). Furthermore, evidence for a
central role of cytokinin and cytokinin perception
downstream of Nod-factor signal transduction
comes from the additive effect of snf1-1 and snf2
mutations. The snf1-1 mutants synthesize a
CCaMK protein impaired in autophosphorylation
(20, 21) and develop an average of 7 ± 0.9 (95%
confidence interval) spontaneous nodules, where-
as snf2 mutants develop 3 ± 0.5. The snf1-1 snf2
double mutants exceed both with 17 ± 0.9 spon-
taneous nodules. Parallel signaling cannot be
excluded, but more likely, the deregulated sig-
naling in snf1 results in a local increase in cyto-
kinin levels transcriptionally up-regulating snf2
(Fig. 2D) and amplifying spontaneous nodulation.
The previously reported expression of a Nin-GUS
promoter fusion in snf1 nodule primordia and the
absence of epidermal expression in snf1 roots (20)
further suggest cytokinin signaling is a cortical
response. Conversion of cortical cells into nodule
stem cells or subsequent organ development seem
therefore tightly controlled. We tested this in a
hypernodulating har1-1 mutant (22). Homozy-
gous snf2 har1-1 double mutants developed an
average of 14 ± 1.4 spontaneous nodules, whereas
snf2mutants developed an average of 3 ± 0.5, and
har1-1, none (fig. S6). This indicates that only a
few cells dedifferentiate or that only a few
dedifferentiated cells sustain cell divisions during
the snf2 nodule-initiation process. The shoot
controlled autoregulation of the root nodule
number (22) is thus acting downstream of
cytokinin signaling–induced activation of root
nodule founder cells (Fig. 4C).
From Arabidopsis and tobacco, there is evi-
dence for cytokinin regulation of cell cycle phase
transitions (23) and for overlapping roles for three
AHK receptors in maintaining stem cells and cell
divisions during organ formation (13). Phytohor-
mones have also been implicated in nodule or-
ganogenesis. Applications of auxin transport
inhibitors resulted in empty nodule-like structures,
which suggested that local inhibition of auxin
transport (24) sensitizes cells for division. Other
experiments showed that externally supplied
cytokinin induces cortical cell division and acti-
vation of Enod12, Enod40, and Enod2 genes
(4, 25), and expression of a cytokinin biosynthesis
tzs gene in a nodulation-deficient Sinorhizobium
meliloti resulted in nodule-like structures (5).
Here we show conclusively that cytokinin sig-
naling plays an important role in plant meristem
formation and is directly involved in initiating root
nodule organogenesis. The opposite phenotype
effects of the snf2 gain-of-function and hit1 loss-
of-function mutations reported in the accompany-
ing paper (18), together with the reduced nodula-
tion observed after down-regulation of the
corresponding gene in Medicago (26), clearly
demonstrate that cytokinin signaling is necessary
and sufficient for the dedifferentiation and cell
proliferation leading to root nodule formation.
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Differential Antigen Processing by
Dendritic Cell Subsets in Vivo
Diana Dudziak,1 Alice O. Kamphorst,1 Gordon F. Heidkamp,1 Veit R. Buchholz,1
Christine Trumpfheller,2 Sayuri Yamazaki,2 Cheolho Cheong,2 Kang Liu,1 Han-Woong Lee,3
Chae Gyu Park,2 Ralph M. Steinman,2 Michel C. Nussenzweig1,4*
Dendritic cells (DCs) process and present self and foreign antigens to induce tolerance or
immunity. In vitro models suggest that induction of immunity is controlled by regulating the
presentation of antigen, but little is known about how DCs control antigen presentation in vivo. To
examine antigen processing and presentation in vivo, we specifically targeted antigens to two
major subsets of DCs by using chimeric monoclonal antibodies. Unlike CD8+ DCs that express the
cell surface protein CD205, CD8− DCs, which are positive for the 33D1 antigen, are specialized for
presentation on major histocompatibility complex (MHC) class II. This difference in antigen
processing is intrinsic to the DC subsets and is associated with increased expression of proteins
involved in MHC processing.
Lymphoid organ DCs are composed ofdistinct subsets (1–5). In the spleen, twomajor types of DCs are found: The first is
positive for the CD8marker and the C-type lectin
CD205 (CD8+DEC205+), and the second lacks
CD8 but expresses the antigen recognized by the
33D1 monoclonal antibody (mAb) CD8−33D1+.
These subsets reside in different anatomic
locations—CD8+DEC205+ DCs are in the T cell
zone, whereas CD8−33D1+ DCs are in the red
pulp and marginal zone—and the two can be
further distinguished by a number of surface
markers (4, 5) (Fig. 1, A to C, and fig. S1).
CD8+DEC205+ DCs appear to be specialized
for uptake of dying cells and play a unique role in
resistance to certain viral infections (6–8). Nota-
ble among the other distinctions between the two
cell types is the suggestion that CD8+DEC205+
DCs are specialized for cross-presentation, which
is the ability to process nonreplicating antigens
for presentation to T cells by class I molecules of
the major histocompatibility complex (MHCI)
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(7–12). However, a direct comparison of the
capacity of the two subsets to process antigen in
vivo has been lacking.
We identified the antigen recognized by the
33D1 mAb through a combination of gene array
and candidate gene approaches and found it to be
dendritic cell inhibitory receptor–2 (DCIR2)
[Fig. 1, D and E; fig. S2 and (13)]. DCs are
highly enriched in lectins, and in addition to
DCIR2 and DEC205, the CD8+DEC205+ and
CD8−33D1+ DCs differed in expression of a
number of other lectins (Fig. 1D and fig. S2B).
To evaluate regulation of antigen processing
and T cell activation by the two DC subsets in
vivo, we delivered antigens to each cell type in
situ using chimeric aDEC205 (14) and 33D1
antibodies (15) [fig. S3 and (13)]. Delivery of
ovalbumin (OVA) antigen by the injected anti-
bodies was monitored after DC purification by
antigen presentation in vitro to transgenic OT-I or
OT-II Tcells specific for OVA peptides presented
on MHC class I or MHC class II, respectively
(14, 16). As previously reported, purified DCs
targeted with aDEC205-OVA in vivo induced
both OT-I and OT-II Tcell proliferation in vitro,
although the extent of OT-II proliferation was
relatively modest (Fig. 1F) (14, 16). In con-
trast, antigen delivered with the 33D1 antibody
elicited high levels of OT-II but no detectable
OT-I T cell responses (Fig. 1F). B cells and
other non-DCs purified from mice injected
with aDEC205-OVA or 33D1-OVA failed to
present OVA either to OT-I or OT-II T cells
(Fig. 1F). The specificity of targeting was
made apparent by the specific localization of
aDEC205 on CD8+DEC205+ DCs and 33D1 on
CD8−33D1+ DCs after chimeric antibody in-
jection in vivo (Fig. 1G). In addition, both anti-
bodies were internalized by the cells, although
the kinetics of 33D1 internalization was slower
than for DEC205, and the amount of internalized
aDEC205-OVA was greater than the amount of
internalized 33D1-OVA (Fig. 1H and fig. S4).
Neither antibody altered DC maturation status, as
determined by surface expression of MHCII,
CD40, CD69, CD80, and CD86 (fig. S5). Finally,
the difference in presentation between the two DC
subsets in vivo was not due to a difference in their
ability to present peptides once processed, because
the two were equivalent in presentation of antigen
to the same transgenic Tcells when processed pep-
tides were added to in vitro cultures (fig. S6). We
conclude that DCs targeted by aDEC205-OVA
or 33D1-OVA in vivo are distinct in their ability
to present antigen on MHCI and MHCII in vitro.
To examine T cell activation in response to
antigen presentation in vivo, we labeled OT-I
and OT-II T cells with 5-(6)-carboxyfluorescein
diacetate succinimidyl diester (CFSE), a reporter
dye for cell division, and monitored the cells
after adoptive transfer to a new host (13). As
observed in vitro, aDEC205-OVA inducedMHC
class I–restricted OT-I responses with greatest
efficiency, whereas 33D1-OVA primarily elic-
ited MHC class II–restricted OT-II responses
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Fig. 1. CD4 and CD8 T cell responses to targeted antigen in vitro. (A) Micrograph shows im-
munohistochemistry of 33D1 (green), aDEC205 (red), and aB220 (blue). (B and C) Dot plots show
splenocytes analyzed by flow cytometry for expression of CD11c and 33D1 (B) and 33D1 and DEC205
gated on CD11chigh cells (C). Numbers indicate percentages of total splenocytes and CD11c+
splenocytes, respectively. (D) Affymetrix gene array analysis of candidate C-type lectins. RNA was
prepared from FACS-sorted B cells, CD4+ T cells, CD8+ T cells, CD8+DEC205+, and CD8−33D1+ WT (−)
and Flt3L-melanoma (+) injected mice. Each bar represents a mean of three individual gene arrays.
List of candidate genes showing difference between CD8+DEC205+ and CD8−33D1+ subsets in WT- and
Flt3L-injected mice. (E) Histograms show 33D1-A647 (black) and isotype IgG2b-A647 antibody (gray)
staining of 293T cells transiently transfected with the indicated cDNAs. (F) Graphs show [3H]thymidine
incorporation by 105 OT-I (upper panels) or OT-II T cells (lower panels) cultured with the indicated
numbers of DCs, B cells, or non-B non-DCs purified from C57BL/6 mice injected with 10 mg of 33D1-
OVA, aDEC-OVA, or Iso-OVA 12 hours earlier. (G) Histogram shows extracellular aDEC205 or 33D1
antibodies on CD8+DEC205+ and CD8−33D1+ DCs 30 min after intravenous injection of 10 mg of
aDEC205-OVA, 33D1-OVA, or Iso-OVA control, visualized with anti-mouse IgG-FITC (fluorescein
isothiocyanate). (H) Histograms show internalization of purified rat 33D1 (upper panels) or rat
aDEC205 antibodies (lower panels) after incubation at 37°C for 0, 30, or 60 min (black), or cell surface
expression after incubation on ice for a further 0, 30, or 60min (gray). Cells were gated on CD11c+CD8−
and CD11c+CD8+ DCs.
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(Fig. 2A). By in vivo dose-response exper-
iments, comparing cell division and T cell ex-
pansion after transfer, 33D1-OVAwas a factor
of 10 less effective in presentation to OT-I T
cells and 10 times as effective in presentation to
OT-II T cells as aDEC205-OVA (Fig. 2, A and
B). Antigen presentation after a single ad-
ministration of either aDEC205-OVA (16) or
33D1-OVA was long-lasting (Fig. 2C). Thus,
OT-I T cells proliferated in response to antigen
even when they were transferred 10 days after
aDEC205-OVA injection, and OT-II Tcells pro-
liferated when cells were transferred up to 5
days after 33D1-OVA injection (Fig. 2C). How-
ever, T cells proliferating in response to antigen
delivered by targeting antibodies in the steady
state were rapidly deleted, and the remaining
cells were unresponsive to further stimulation in
vitro (Fig. 2, D and E). In contrast, when antigen
delivery by 33D1 was combined with DC ac-
tivation by aCD40, the expanded T cell pop-
ulation persisted and demonstrated strong recall
responses to antigen challenge in vitro (Fig. 2, F
and G). Thus, antigen delivery to CD8−33D1+
DCs in vivo results in preferential MHCII-
restricted antigen presentation. Nevertheless,
delivery of antigens to both DC subsets in the
steady state leads to T cell tolerance, whereas
targeting in combination with DC maturation
by CD40 ligation leads to expansion of T cell
clones that remain responsive to antigen.
To examine the mechanism responsible
for differential antigen presentation by the two
DC subsets, we assayed formation of MHCII
hen egg lysozyme (HEL) peptide complexes
(MHCII-p) by using a mAb specific for this
complex (17). CD8+DEC205+ DCs showed
small amounts of surface MHCII-p 3 hours after
injection of aDEC205-HEL, but this was no
longer visible after 1 day (Fig. 3A). In contrast,
CD8−33D1+ DCs targeted with 33D1-HEL
antibodies displayed much higher levels of
MHCII-p after 3 hours and continued to display
MHCII-p 2 days after targeting (Fig. 3A, ar-
rows). MHCII-p formation was specific for
the targeting antibody and independent of
DC activation because mice deficient in the
lipopolysaccharide (LPS) Toll-like receptor 4
(TLR-4) were indistinguishable from controls in
this assay (Fig. 3, A and B) (13). We conclude
that antigens delivered by the 33D1 antibody to
CD8−33D1+ DCs in the steady state are pro-
cessed and transferred to the cell surface as
MHCII-p more efficiently than are antigens de-
livered by aDEC205 to CD8+DEC205+ DCs.
To determine whether the observed differ-
ences in antigen processing were due to cell-
intrinsic differences between the two DC subsets,
we produced transgenic mice that express human
DEC205 (CD11c-hDEC205 B10.BR transgenic
mice) on both DC subsets and performed tar-
geting experiments with an ahDEC205 antibody
that does not cross-react with mouse DEC205
(18) [fig. S7; note that CD11c-hDEC205 mice
show position effect variegation and hDEC205 is
equally expressed and variegated on both DC
subsets (13)]. Both subsets were specifically
targeted by ahDEC205-HEL in transgenic mice
but not wild-type (WT) controls in vivo as
measured by surface staining with antibodies to
immunoglobulin G (anti-IgG) (fig. S8). How-
ever, only CD8−33D1+ CD11c-hDEC205 trans-
genic DCs showed high levels of MHCII-p after
ahDEC205-HEL or MHCII-p presentation after
ahDEC205-OVA injection (Fig. 3C and fig. S9).
To further compare presentation by aDEC205-
OVA and 33D1-OVA targeting in the same
cell, we infected bone marrow–derived DCIR2-
negative DCs with a retrovirus encoding DCIR2
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Fig. 2. CD4 and CD8 T cell responses to targeted antigen in vivo. (A) Histograms show proliferation as
measured by CFSE dye dilution by OT-I (left) or OT-II (right) T cells 3 days after injection of varying
amounts of 33D1-OVA, aDEC-OVA, or control antibodies. (B) Dot plots show the relative numbers of
OT-I (upper panels) or OT-II (lower panels) T cells remaining in spleen 3 days after injection of 300 ng of
33D1-OVA, aDEC-OVA, or Iso-OVA. Numbers indicate percentages of gated CD4+ or CD8+ that were
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www.sciencemag.org SCIENCE VOL 315 5 JANUARY 2007 109
REPORTS
and green fluorescent protein (GFP) (fig. S10A).
Infected cells expressing the retrovirally encoded
DCIR2 were then sorted on the basis of GFP
expression and targeted with aDEC205-OVA or
33D1-OVA in vitro. Following DC maturation
with LPS, presentation to OT-II T cells was
equivalent for the two targeting antibodies [fig.
S10B and (13)]. This shows that class II pre-
sentation by mature bone marrow–derived DCs
(BMDCs) was independent of whether they were
targeted by aDEC205-OVA or 33D1-OVA. We
conclude that the difference inMHCII processing
by DC subsets is an intrinsic property of the cell
and not due to differences between the receptors
targeted by aDEC205 or 33D1 mAbs.
Many of the proteins that regulateMHCI and
MHCII processing pathways have been de-
scribed and their expression documented in
DCs (19, 20). To determine whether the two
DC subsets show systematic intrinsic differences
in expression of components of the MHCI and
MHCII processing machinery, we performed
microarray experiments onmRNA isolated from
the two DC subsets (Fig. 4, A and B; fig. S11A)
(13). We found that the two DC subsets dif-
ferentially express components of the MHCI and
MHCII processing pathways in a manner con-
sistent with their ability to produce MHCII-p
and induce CD4 and CD8 T cell responses.
CD8+DEC205+DCs, which are biased forMHCI
cross-presentation, were enriched in Tap1, Tap2,
calreticulin, calnexin, Sec61, ERp57, ERAAP, as
well as cystatin B and C, all of which are
involved in MHCI presentation or inhibition of
enzymes that process peptides for MHCII
presentation (19, 20) (Fig. 4B). In contrast,
CD8−33D1+ DCs, which are biased for MHCII
presentation, were enriched in cathepsins C, H,
and Z, asparagine endopeptidase (AEP), GILT,
and H2-Mbeta 1, all of which are implicated in
theMHCII antigen processing pathway (19, 20)
(Fig. 4A). To confirm that these proteins were
differentially expressed in DC subsets, we per-
formed fluorescence-activated cell sorting
(FACS) analysis for intracellular H2DM (Fig.
4C) and Western blotting experiments. MHCI
processing–associated proteins were expressed
at higher levels in CD8+DEC205+ DCs (Fig.
4E and fig. S11B), whereas MHCII processing
proteins were expressed at higher levels in
CD8−33D1+ DCs (Fig. 4, C to F, and fig. S11B).
We conclude that the differences in expression
of proteins involved in antigen processing in
CD8+DEC205+ and CD8−33D1+ DCs are
consistent with preferential processing of anti-
gens for presentation by the two cell types.
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or control littermate (C57BL/6 × B10.BR) mice (hDEC−). Arrows indicate significant staining as
compared with controls.
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Fig. 4. Distinct expression pattern of MHC class I– and MHC class II–associated molecules. Affymetrix
gene array analysis showing relative amounts of mRNAs associated with the MHC class II (A) and MHC
class I (B) processing pathways expressed by CD8+DEC205+ and CD8−33D1+ DCs purified from WT-
(−) and Flt3L-melanoma– (+) injected mice. Each bar represents the mean of three individual gene
arrays prepared from distinct mRNA samples. (C) Intracellular FACS analysis of H2-DMb1/H2-DMa
heterodimer in the CD8+DEC205+ and CD8−33D1+ DCs. (D) Western blots for cathepsin H, Gilt, and
AEP on extracts of purified CD8+DEC205+ and CD8−33D1+ spleen DCs. (E) Western blots for Tap-1,
tapasin, cystatin C, calnexin, and calreticulin on extracts of purified CD8+DEC205+ and CD8−33D1+
spleen DCs. (D) Lysosomal marker LAMP-1 (lysosomal-associated membrane protein 1) and (F) b-actin
are shown as loading controls.
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Efficient antigen presentation by DCs re-
quires regulated lysosomal protein degradation
(21, 22). However, the requirements for presen-
tation on MHCII and cross-presentation on
MHCI differ in that MHCII processing occurs
inside endosomes, whereas cross-presentation on
MHCI necessitates antigen escape from the endo-
some into the cytoplasm to gain access to the
proteasome andTAP transporters (19, 20, 23–25).
Elegant in vitro experiments with cultured DCs
show that during DC development, antigen
presentation is regulated through control of
lysosomal processing and MHCII cell surface
transport (21, 22, 26–28). Cultured immature
DCs capture antigen but only process and present
it on MHCII after exposure to inflammatory
stimuli or TLR ligation (22). This unique ability
to sequester antigens may be important for their
preservation during DC transit from sites of in-
flammation to lymphoid organs and might facil-
itate the escape of antigen from endosomes to the
cytoplasm or endoplasmic reticulum for cross-
presentation (21). However, DCs that fail to de-
grade antigen might also be suboptimal producers
of MHCII-p. Our experiments show that in the
intact host, this problem is resolved by producing
a subset of DCs specialized for maximizing
MHCII presentation. Although CD8+DEC205+
DCs can initiate immune responses by presenting
on MHCII, CD8−33D1+ DCs excel in producing
MHCII-p. This specializationmay have important
implications for understanding the initiation of
T cell responses in vivo and for rational vaccine
design.
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Differential Transmission of Actin
Motion Within Focal Adhesions
Ke Hu,* Lin Ji,* Kathryn T. Applegate, Gaudenz Danuser,† Clare M. Waterman-Storer†
Cell migration requires the transmission of motion generated in the actin cytoskeleton to the
extracellular environment through a complex assembly of proteins in focal adhesions. We developed
correlational fluorescent speckle microscopy to measure the coupling of focal-adhesion proteins to
actin filaments. Different classes of focal-adhesion structural and regulatory molecules exhibited
varying degrees of correlated motions with actin filaments, indicating hierarchical transmission of
actin motion through focal adhesions. Interactions between vinculin, talin, and actin filaments appear
to constitute a slippage interface between the cytoskeleton and integrins, generating a molecular
clutch that is regulated during the morphodynamic transitions of cell migration.
Directed cell migration involves spatio-temporal orchestration of protrusion atthe leading cell edge, adhesion of the
protrusion to the extracellular matrix (ECM),
pulling against the adhesions to translocate the
cell body, and weakening of the adhesion at the
cell rear for advancement (1). In this process,
actin filaments (F-actin) must couple to the ECM
through the plasma membrane (1–3) via focal
adhesions (FAs) to translate actin polymeriza-
tion and/or actin-myosin contraction into cell
motion. FAs are complexes of >100 different
proteins linking F-actin to clustered transmem-
brane integrin ECM receptors (2, 4). Regulating
the attachment between F-actin and integrins via
proteins within FAs is thought to be critical for
controlling the spatiotemporal variability of pro-
trusion and traction (5) and the ability of cells to
respond to mechanical cues.
It is well established that F-actin and FAs are
coupled to each other. Many FA proteins bind
directly or indirectly to F-actin (6–8) and/or
integrins (9–13). Contractile actomyosin bun-
dles are often rooted in FAs (2, 4), and per-
turbations of actomyosin cause changes in
FAs and vice versa (2). Although the impor-
tance of spatiotemporal coordination between
FAs and F-actin in cell migration is well ap-
preciated (2, 14, 15), it is not known which
FA molecules interact with F-actin in living
cells, and the dynamics of molecules within
these two assemblies have never been analyzed
simultaneously. Predicting how FA proteins
behave in vivo by biochemical data alone is
impossible because of the complexity of their
interactions (4).
To study the dynamic interactions between
F-actin and FAs, we combined total internal re-
flection fluorescence microscopy (TIRFM) and
fluorescent speckle microscopy (FSM). TIRFM
optimizes image contrast at the ventral cell–
ECM/coverslip interface where cortical F-actin
integrates with FAs. FSM marks macromolec-
ular assemblies with fluorophore clusters called
speckles (fig. S1). Computational tracking of
speckle motion allows mapping of protein dy-
namics with submicron resolution (16, 17). We
studied PtK1 cells migrating on coverslips, on
which they organized a fibronectin-containing
ECM (fig. S2).
To determine the spatial relations between
FAs and F-actin flow, we captured image pairs
using TIRFM of green fluorescent protein
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